NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.00 Average PT from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $14.00.

NPCE has been the topic of several research reports. Wells Fargo & Company lowered their price target on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Morgan Stanley lowered their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th.

Institutional Trading of NeuroPace

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after purchasing an additional 75,512 shares in the last quarter. Acadian Asset Management LLC acquired a new position in NeuroPace in the first quarter valued at about $621,000. Hillsdale Investment Management Inc. acquired a new position in NeuroPace in the first quarter valued at about $155,000. Bank of New York Mellon Corp bought a new stake in NeuroPace during the second quarter worth about $257,000. Finally, Financial Advocates Investment Management increased its holdings in shares of NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after buying an additional 5,000 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Trading Up 2.8 %

Shares of NASDAQ:NPCE opened at $7.43 on Wednesday. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37. The stock’s 50-day moving average is $7.40 and its 200-day moving average is $9.68. The company has a market cap of $216.96 million, a P/E ratio of -6.24 and a beta of 1.80. NeuroPace has a 52-week low of $5.75 and a 52-week high of $18.15.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The firm had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company’s revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) EPS. Equities research analysts predict that NeuroPace will post -1.08 earnings per share for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.